Sesen Bio is a clinical-stage biopharmaceutical company that developed targeted fusion protein therapeutics for cancer, particularly Vicineum for non-muscle invasive bladder cancer
Sesen Bio is a clinical-stage biopharmaceutical company that developed targeted fusion protein therapeutics for cancer, particularly Vicineum for non-muscle invasive bladder cancer. Its engineered fusion proteins combine a tumor-targeting antibody fragment with a cytotoxic protein payload to selectively attack cancer cells while limiting harm to healthy tissue. Sesen Bio later entered a merger agreement with Carisma Therapeutics, whose focus is engineered macrophage cell therapies.